Please find all related articles below.
11 December 2014 - The public health community calls on Mr Juncker, President of the European Commission, to reconsider his decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.
To Jean-Claude Juncker, President of the European Commission
We followed attentively your speech before the European Parliament on 22 October (...)
November 2014 - The new Commission under President Jean-Claude Juncker officially took office on 1st November. EPHA has closely monitored the evaluation process of the new College of Commissioners and collected the health relevant commitments the Commissioners for Health and Food Safety; Internal Market, Industry, Entrepeneurship and SMEs; and Employment, Social Affairs, Skills and Labour Mobilty.
Vytenis Andriukatis, Commissioner for Health and Food Safety (EPHA evaluation of his (...)
28 October 2014, Brussels – MEPs, patients and the European public health community are today asking President-elect Juncker to clarify whether medical devices and health technologies will remain in the directorate for health or not. Fears over patient safety remain as Mr Juncker has so far failed to publicly clarify his ambiguous statement (1) last week to the European Parliament.
Last week’s statement of the European Commission’s President-elect that the competence for (...)
Further to our Joint Letter of 16 September 2014 (1) , we are contacting you again to express our gratitude for your decision (2) to move the competence for medicines and pharmaceutical products back into the hands of the European Commissioner for Health. We firmly believe that this directorate is best placed to ensure a good balance between economic and public health objectives while promoting ‘smart, sustainable and inclusive’ growth for Europe.
28 October 2014, Brussels (...)
October 22th 2014, Brussels – The NGO signatories of this statement wholeheartedly welcome the announcement of the reversal of the decision by President-elect Jean-Claude Juncker to move the competence for pharmaceutical and medical devices to the enterprise directorate (1).
Following negotiations within the European Parliament and concerns expressed by a number of member states, President-elect Juncker stated today that the "responsibility for medicines and pharmaceutical products (...)
October 10th 2014, Brussels – According to statements by both the S&D (1) and Green Groups (2) yesterday, it seems likely that President-elect Jean-Claude Juncker is intending to soften his decision to move pharmaceutical policy from the health portfolio to enterprise. EPHA welcomes this news as a step in the right direction and a possible cause for celebration for the European Parliament (3) and the public health community (4).
“I would like to applaud President-elect (...)
October 8 2014, Brussels - On 10th of September, the European Commission President-elected Jean-Claude Juncker unveiled the transfer of the competence for medicinal products and health technologies from the health portfolio to the enterprise one (now called Internal Market, Industry, Entrepreneurship and SMEs).
Dear Member of European Parliament,
The shift of EU pharmaceutical policy will put Europe’s security at risk and is in contradiction with how pharmaceutical policy is (...)
1 October 2014, Brussels - By European Parliament standards, Commissioner-designate Vytenis Andriukaitis’ performance could be judged to be “satisfactory”. He showed his commitment to protect European citizens’ health and well-being, and improve underlying determinants of health and physical environment. Now we will really have to see how he intends to turn words into concrete action. He was very outspoken on the issues of prevention, promotion and protection of (...)
September 29 2014, Brussels - When questioning the EU Commissioners-designate this week, Members of the European Parliament (MEPs) should reject the decision by Jean-Claude Juncker, the European Commission President-elect, to move pharmaceutical policy from the health to the enterprise portfolio (1). The main driver of EU policies concerning pharmaceuticals and health technologies should be promoting and protecting health and patient safety, not simply boosting the competitiveness of the (...)
Brussels, 16 September 2014 - We are writing to express our astonishment and concern regarding your decision to move the competence for medicinal products and health technologies from the Commissioner in charge of Health to the Commissioner in charge of internal market and industry within the new Commission.
Dear Mr Jean-Claude Juncker, President-elect of the European Commission,
The economic crisis, the ageing of the population, technological advances, and new health threats, including (...)